Mesothelioma is a rare malignancy involving the serous lining of body cavities (pleura, peritoneum, pericardium or tunica vaginalis testis).
Epidemiology
Incidence
2500-3000 new cases annually in the U.S.
Occurrence is rising in males ≥75 years old; however, it is not in males and females <75 years old (coincides with OSHA restrictions of permissible limits of asbestos exposure)
Maximum lifetime risk in 1925-1929 birth cohort
Age – peak age 40-60 years
Gender – strong male predominance
Risk factors
Asbestos exposure (amphiboles more carcinogenic than chrysotile fibers)
80% of mesothelioma cases occur in patients with history of asbestos exposure
At-risk occupations include shipbuilding, construction, fireproofing, automobile brakes and clutches, ceiling tiles, boilers (especially in construction prior to 1970)
For fixed tissue samples,consultative services as well as immunohistochemical staining for AE1/AE3 (Pan cytokerat), Ber-Ep4, Calretinin, CEA, CK 5/6, CK-7, E-Cadherin, EMA, ERA (moc-31), Keratin 903 (HMW) and WT-1 (monoclonal) are available
Soluble Mesothelin Related Peptides (MESOMARK®) 0081284
Method: Enzyme-Linked Immunosorbent Assay
Monitor mesothelioma
Not a diagnostic test
Humanitarian use device which requires IRB approval for use
Requires serial measurements
Additional Information
Interpretation of most stains is only available in conjunction with a consultation. Stains can be performed and returned for client pathologists to interpret unless noted.
General References
Carbone M, Bedrossian CW.The pathogenesis of mesothelioma.Semin Diagn Pathol. 2006;23(1):56-60. (Link to PubMed)
Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C.Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.Ann Oncol. 2006;17(11):1615-1619. (Link to PubMed)
Ho L, Sugarbaker DJ, Skarin AT.Malignant pleural mesothelioma.Cancer Treat Res. 2001;105:327-373. (Link to PubMed)
King JE, Thatcher N, Pickering CA, Hasleton PS.Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.Histopathology. 2006;48(3):223-232. (Link to PubMed)
Ordonez NG.The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.Am J Surg Pathol. 2003;27(8):1031-1051. (Link to PubMed)
Pistolesi M, Rusthoven J.Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.Chest. 2004;126(4):1318-1329. (Link to PubMed)
West SD, Lee YC.Management of malignant pleural mesothelioma.Clin Chest Med. 2006;27(2):335-354. (Link to PubMed)
Zucali PA, Giaccone G.Biology and management of malignant pleural mesothelioma.Eur J Cancer. 2006;42(16):2706-2714. (Link to PubMed)
Reviewed by
Bentz, Joel S., M.D., M.S. Associate Professor, Pathology, University of Utah
Grenache, David G., Ph.D. Medical Director, Special Chemistry at ARUP Laboratories; Assistant Professor, Clinical Pathology, University of Utah
Comprehensive Review: May 2008
Last Update: May 2008